drugset / Trial / NCT04900428

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)

NCT04900428 ↗

Phase 2 Terminated 179 enrolled Sorrento Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have mild symptoms.

Timeline

Start
2021-07-16
Primary completion
2022-03-22
Completion
2022-05-06

Outcome

Outcome not reported

Stopped: “Study was terminated at interim analysis due to drops not working on new variants”

Drugs

EvaluationDrugModalityDoseRoute
Subject PLUTAVIMAB Monoclonal antibody 10 mg Intranasal
Subject PLUTAVIMAB Monoclonal antibody 20 mg Intranasal

Indications